Lataa...
Severe sepsis: are PROWESS and PROWESS-SHOCK trials comparable? A clinical and statistical heterogeneity analysis
Despite the same manufacturer, the same drotrecogin alfa activated dose, and the same placebo-controlled design, the negative result from the PROWESS-SHOCK trial contradicted the survival benefit observed in the PROWESS trial. We hypothesize that the different results were due to factors other than...
Tallennettuna:
| Päätekijät: | , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
BioMed Central
2013
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3706817/ https://ncbi.nlm.nih.gov/pubmed/23826709 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/cc12752 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|